The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.

The aim is to provide a novel compound that can luminesce with high brightness and be used as a luminescent substrate in a firefly bioluminescence system. Provided is a heterocyclic compound, or salt thereof, represented by the following general formula (1): ##STR00001##
[R.sup.1, R.sup.2, and R.sup.3 are independently hydrogen or an alkyl group having a carbon number of 1-4, with provisos that R.sup.1 and R.sup.2 are optionally bonded to form a ring and that one of R.sup.1 and R.sup.2 is optionally bonded to Y.sup.1 to form a ring; X is S, O, NR.sup.4, or CH.sub.2, and Y.sup.1 and Y.sup.2 are independently N or CR.sup.4, where each R.sup.4 is independently hydrogen, an alkyl group having a carbon number of 1-4, an alkenyl group having a carbon number of 2-4, or an acyl group having a carbon number of 2-4; n is an integer of 0-4].

The present invention covers aminothiazole compounds of general formula (I), in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGKζ) regulated disorders, as a sole agent or in combination with other active ingredients.

##STR00001##

Disclosed herein are small molecule modulators, compositions, formulations, and methods of use of a novel skin care treatment.

Disclosed herein are small molecule modulators, compositions, formulations, and methods of use of a novel skin care treatment.

The disclosure provides compounds and method useful for modulating gp130 biological activity. The disclosure also provides methods and compositions for treating disease and disorders associated with gp130 activity, particularly those associated with inflammation.

The present specification relates to an organic light emitting diode.

The present specification relates to an organic light emitting diode.

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

The present invention provides compounds inhibiting elF4E activity, and compositions and methods of using thereof. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with elF4E. Such diseases, disorders, or conditions include cellular proliferative disorders (e.g., cancer) such as those described herein.